Human paraoxonase,PON ELISA Kit

Code CSB-E09484h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
paraoxonase 1
Alternative Names
A esterase 1 ELISA Kit; A-esterase 1 ELISA Kit; Aromatic esterase 1 ELISA Kit; Arylesterase 1 ELISA Kit; Arylesterase B type ELISA Kit; ESA ELISA Kit; Esterase A ELISA Kit; K 45 ELISA Kit; K-45 ELISA Kit; MVCD5 ELISA Kit; Paraoxonase 1 ELISA Kit; Paraoxonase ELISA Kit; Paraoxonase B type ELISA Kit; Paraoxonase, plasma ELISA Kit; Paraoxonase1 ELISA Kit; PON 1 ELISA Kit; PON ELISA Kit; PON1 ELISA Kit; PON1_HUMAN ELISA Kit; Serum aryldiakylphosphatase ELISA Kit; Serum aryldialkylphosphatase 1 ELISA Kit; Serum paraoxonase/arylesterase 1 ELISA Kit
Abbreviation
PON1
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, cell culture supernates, tissue homogenates
Detection Range
31.25 mIU/mL-2000 mIU/mL
Sensitivity
7.81 mIU/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Cardiovascular
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human PON in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
 SampleSerum(n=4)
1:100Average %88
Range %80-92
1:200Average %98
Range %91-105
1:400Average %103
Range %92-110
1:800Average %93
Range %86-98
Recovery
The recovery of human PON spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9389-98
EDTA plasma (n=4)9590-100
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
mIU/mlOD1OD2AverageCorrected
20002.655 2.603 2.629 2.521
10002.292 2.248 2.283 2.175
5001.689 1.663 1.676 1.568
2501.025 0.989 1.007 0.899
1250.597 0.603 0.600 0.492
62.50.409 0.398 0.404 0.296
31.250.218 0.229 0.224 0.116
00.109 0.107 0.108  
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This human paraoxonase (PON1) ELISA kit employs the quantitative sandwich enzyme immunoassay technique to measure the levels of human PON1 in different samples, including serum, plasma, cell culture supernates, or tissue homogenates. The enzyme-substrate chromogenic reaction is also used to amplify the signal and quantify the levels of the analyte through the intensity of the colored product. The color intensity positively correlates with the amount of PON1 bound in the initial step.

PON1 is a phase-I enzyme involved in the hydrolysis of organophosphate esters. As a high-density lipoprotein (HDL)-associated esterase, PON1 can hydrolyze oxidized LDL-cholesterol, with potential atheroprotective effects. IT also mediates protection against lipid oxidation. PON1 not only has a weak paraoxonase activity but also exhibits anti-oxidant and anti-inflammatory activities. It is implicated in several human diseases, including diabetes mellitus and atherosclerosis. Low PON1 activity has been related to the elevated risk of major cardiovascular events.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation.
Gene References into Functions
  1. serum levels decrease in states of high oxidative stress like metabolic syndrome, obesity, uncontrolled diabetes, and dyslipidemia PMID: 29843993
  2. CD was found to be associated with the decrease in the levels of PON-1, which correlates well with activity of the disease and reflects the intensification of inflammation, as well as intensified lipid peroxidation. High sensitivity and specificity of PON-1 determines its selection as a good screening test for CD severity. PMID: 30314292
  3. The analysis of the effect of the individual SNPs(PON1, IL-6, ITGB3, and ALDH2 ) and GRS groups on different lipid profile parameters revealed no significant association of any of the tested SNPs with any lipid parameter, however, the GRS groups showed marginally significant for TC and highly significant association for TG, LDL-c and HDL-c PMID: 30261890
  4. It findings provide genetic evidence that the PON1-L55M variant may be a factor contributing to the glycemic control in type 2 diabetes. PMID: 29782842
  5. Low serum paraoxonase 1 activity is associated with the development of type 2 diabetes mellitus. PMID: 29156090
  6. T allele and TT genotype are associated with COPD, and the PON1-108C>T polymorphism could be a potential predictor of the disease. PMID: 29858231
  7. study showed that altered HDL subclasses distribution, changed PON1 activities on different HDL subclasses as well as diminished anti-oxidative protection could be important factors in atherosclerosis development in CKD and ESRD patients PMID: 30130521
  8. Data suggest that patients with ARF (acute renal failure) caused by septic shock have low serum PON1 activities, cholesterol, and HDL-cholesterol; high serum PON1 activities are associated with severity of septic shock; extra-renal depuration techniques produce further increases in serum PON1 activities related to duration of stay in ICU and increases in serum urea levels. This study was conducted in Spain. PMID: 30165052
  9. Studied association of genetic polymorphisms of paraoxanase 1(PON1) in Turkish patients with pulmonary embolism (PE). Results suggest that there is no relationship between both PON 1 polymorphisms and PE in the Turkish population. PMID: 29682786
  10. Low PON1 expression is associated with breast cancer. PMID: 29970690
  11. serum concentrations of trace elements and their relationships with paraoxonase-1 in morbidly obese women PMID: 29773198
  12. Low PON1 expression is associated with Atherosclerosis. PMID: 29254890
  13. The aim of this study was to investigate whether obesity is associated with PON1 activity and whether this association is influenced by oxidative stress, inflammation and HDL cholesterol (HDL-C) concentration. PMID: 29168398
  14. Our results showed that ApoE epsilon4 and PON1-55M alleles act synergistically to increase the risk of systemic lupus erythematosus by 1.47 times PMID: 29273831
  15. Low PON1 expression is associated with endometrial cancer. PMID: 30178714
  16. The rs3735590 polymorphism of PON1 acts as a prognostic biomarker in COPD patients treated by CABG. PMID: 29953969
  17. Results showed significantly decreased levels of PON1 in patients with chronic liver diseases (controls 185 +/- 14 U/l, NAFLD 160 +/- 15 U/l, chronic hepatitis 99 +/- 18 U/l, cirrhosis (52 +/- 11 U/l). PMID: 29322801
  18. rs662_A allele carriers may benefit from intake of vegetables and thus be more effectively protected from ischemic stroke. Carriers of the G allele may still remain at greater risk for ischemic stroke even when they consume a high level of vegetables. PMID: 29215590
  19. Impaired anti-oxidant and anti-atherogenic HDL properties associated with weakened PON1 function and lipid peroxidation may contribute to the development of atherosclerosis-related diseases in T2DM. PMID: 29626583
  20. the Q192R polymorphism in the PON1 gene is associated with familial hypercholesterolemia (FH) in the Saudi population; the R allele, QR, and dominant model genotypes were associated with FH PMID: 29229890
  21. activity of PON1 in the control group was significantly higher in comparison with diabetic patients PMID: 28866115
  22. PON1-L55M T alleles are associated with dementia risk. PMID: 28657841
  23. PON1 Q192R polymorphism has a weak association with coronary heart disease risk in Chinese PMID: 29952962
  24. rs854560 polymorphism may modulate the risk of coronary artery disease in response to cigarette smoking in Polish population. PMID: 29118461
  25. PLA2G7 and PON1 are overexpressed in prostatic neoplasm patients and can be detected early in blood. PMID: 29050675
  26. PON1 as an important candidate gene influencing genetic pathophysiology of polycystic ovarian syndrome. PMID: 29604466
  27. It demonstrates that the impact of Y71 substitutions on PON1's lactonase activity is minimal, whereas the kcat for the paraoxonase activity is negatively perturbed by up to 100-fold, suggesting greater mutational robustness of the native activity. PMID: 28026940
  28. genetic association studies in population of women in Greece: Data suggest than a genetic polymorphism in PON1 (Q192R) is associated with gestational diabetes in the population studied. Transcription of the PON1 gene does not appear to be impaired in leukocytes from women with gestational diabetes. PMID: 28347194
  29. The patients with CT OR TT genotype at loci rs3735590 had a lower risk of CAVS than patients with the CC genotype. PMID: 29462797
  30. HDL-C, but not its anti-oxidant constituent, PON-1, is inversely, continuously and independently associated with future risk of hypertension. PMID: 28667918
  31. In donor retina from patients with diabetes, all three PON1, PON2 and PON3 were expressed, and there was a significant increase in PON3 expression compared to control. This might be the reason for the increased thiolactonase activity observed in diabetic retina compared to control PMID: 28862184
  32. Serum PON1 levels showed that oxidative stress was severe in otosclerosis. PMID: 27387094
  33. PON1 L55M genetic polymorphisms may be associated with the risk of breast cancer and could potentially serve as useful genetic markers for tumor prognosis in some populations of Chinese women. PMID: 28445984
  34. Paraoxonase-1 (PON1) induces metastatic potential and apoptosis escape via its antioxidative function in lung cancer cells PMID: 28467805
  35. This study is the first study to investigate serum PON1 enzyme activity in patients with cutaneous anthrax. We concluded that oxidative stress was increased whereas serum PON1 activity was decreased in patients with cutaneous anthrax. These results indicate that lower PON1 activity is associated with an oxidant-antioxidant imbalance. PMID: 27461010
  36. The L55M polymorphism associated with systemic lupus erythematosus and anti-phospholipid syndrome in a population from Cairo, Egypt, while the Q192R polymorphism played no role in disease susceptibility. PMID: 28185016
  37. PON1 (Q192R and L55M) polymorphisms may play a crucial role in pathogenesis and susceptibility of insulin resistance thus leads to the development of type 2 diabetes in South Indian population. PMID: 29409844
  38. PON1 protein can be detected in plasma and resides in the high-density lipoprotein fraction and protects against Oxidative stress by hydrolyzing certain oxidized lipids in lipoproteins, macrophages and Atherosclerotic lesions. PMID: 29308836
  39. Our study provides preliminary support for the involvement of organophosphate pesticides and PON1 in Parkinson's disease-related motor, cognitive, or depressive symptom progression. PMID: 28689109
  40. The distribution of genotype frequencies in the assessed women (PON1 Q192R polymorphism) was QQ = 20%, QR = 48% and RR = 32%. Significantly higher serum FABP4 levels were found in women with genotype QR/RR (20.6 +/- 2.20 ng/mL), when compared with the levels found in the QQ group (12.8 +/- 1.70 ng/mL) (p = .004). PMID: 27712128
  41. rare genetic variation in PON1 was associated with ischemic stroke, with stronger associations identified in those of AA. Increased focus on PON1 enzyme function and its role in cerebrovascular disease is warranted. PMID: 24711634
  42. PON1 arylesterase activity correlated negatively with sCD40L, ADMA, and sICAM-1 levels in overweight patients with newly diagnosed untreated hyperlipidaemia. PMID: 28602123
  43. 5-amino-2-methylbenzenesulfonamide showed competitive inhibition and so molecular docking studies were performed for this compound in order to assess the probable binding mechanism into the active site of hPON1. PMID: 28665493
  44. The results of various studies in different populations indicate that some SNPs of the PON1 gene are associated with stroke. PMID: 28779954
  45. Genotype RR of PON1 Q192R is an independent risk factor predicting re-stenting in Chinese acute coronary syndrome patients after coronary stenting PMID: 27450784
  46. Clinical observations focusing on gene polymorphisms of PON indicate that three different genotypes of polymorphism PON1Q192R have unequal degrees atheroprotective properties. PMID: 29215249
  47. the measurement of serum PON1 concentration post-radiotherapy (RT) could be an efficient prognostic biomarker, and may be used as an index of the efficacy of the RT. PMID: 29176871
  48. Patients with the Q allele of the PON1 Q192R polymorphism who were treated with statins exhibited improvement in glucose metabolism, especially in insulin secretion, suggesting the importance of genotyping PON1 Q192R to identify those who could benefit from statin therapy. PMID: 29233102
  49. PON1 and CYP2C19 polymorphisms were associated with lower clopidogrel responsiveness in this sample. PMID: 28076455
  50. Our study showed that although lipoic acid up-regulates PON3 but down-regulates PON1 mRNA expression, it increases both PON1 and PON3 protein levels and arylesterase activity in HepG2 cells. We can report that lipoic acid may be useful for preventing atherosclerosis at therapeutic doses. PMID: 28653653

Show More

Hide All

Involvement in disease
Microvascular complications of diabetes 5 (MVCD5)
Subcellular Location
Secreted, extracellular space.
Protein Families
Paraoxonase family
Tissue Specificity
Plasma, associated with HDL (at protein level). Expressed in liver, but not in heart, brain, placenta, lung, skeletal muscle, kidney or pancreas.
Database Links

HGNC: 9204

OMIM: 168820

KEGG: hsa:5444

STRING: 9606.ENSP00000222381

UniGene: Hs.370995

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X